TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

62 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Obesity / overweightHigh cholesterol

    Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity

    Testing whether daily milk polar lipids affect heart and metabolic risk in adults with belly fat and

    📍 University of Connecticut · Storrs, CT · Get directions →

    The major objective of this project is to examine whether daily consumption of milk polar lipids (MPLs) influences cardiometabolic risk factors.

    ✓ Study care freeEarly Phase 1Ages 18–70Learn more →
  • Dementia / Alzheimer'sParkinson's disease

    Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments

    Testing whether a tributyrin supplement helps memory, thinking, and balance in adults with Parkinson

    📍 Domino's Farms · Ann Arbor, MI · Get directions →

    The goal of this clinical trial is to learn if taking a tributyrin supplement works to improve memory and thinking and walking and balance in adults with Parkinson disease Parkinson disease dementia. It will also learn about the safety of tributyrin supplementation.

    ✓ Study care freePhase 1Ages 45+Learn more →
  • Parkinson's disease

    Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms

    Testing a non-invasive brain stimulation device to improve Parkinson’s movement problems

    📍 U LLC Headquarters · Cleveland, OH · Get directions →

    This study tests a new, non-invasive brain stimulation device called Sphere V3.0 to help improve movement problems in people with Parkinson's disease. The device delivers gentle electrical signals to the scalp using small electrodes placed on the head.

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • Parkinson's disease

    Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis

    Testing whether a low-dose seizure medicine can help Parkinson’s psychosis

    📍 Johns Hopkins · Baltimore, MD · Get directions →

    This clinical trial will test whether AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) can improve symptoms of psychosis in Parkinson's disease. Participants will be asked to complete up to 5 in-person study visits over approximately 20 weeks.

    ✓ Study care freePhase 2Ages 40–85Learn more →
  • Parkinson's disease

    A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

    Testing a treatment in people with early Parkinson’s disease who have an LRRK2 gene test result

    📍 Banner Sun Health Research Institute · Sun City, AZ · +39 more US sites · Get directions →

    The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Parkinson's disease

    A Study of Buntanetap in Participants With PD

    Testing the long-term safety of buntanetap in people with Parkinson’s

    📍 University of Alabama at Birmingham · Birmingham, AL · +26 more US sites · Get directions →

    This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study.

    ✓ Study care freePhase 2Ages 40–85Learn more →
  • Dementia / Alzheimer'sParkinson's disease

    PET Imaging Evaluation of [11C]SY08

    Testing a PET scan tracer to detect alpha-synuclein protein clumps in dementia and Parkinson’s

    📍 MGH · Charlestown, MA · Get directions →

    The overall goal of the proposed research is to evaluate the use of \[11C\]SY08 as a PET radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD), Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls. The purpose of this study is to evaluate the use of \[11C\]SY08 as a PET radiotracer for αS fibrils in individuals with PD, MSA, DLB and healthy controls.

    ✓ Study care freeEarly Phase 1Ages 50–80Learn more →
  • Parkinson's disease

    Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies

    Testing an injection for brain scans to study Parkinson’s disease and safety

    📍 Institute for Neurodegenerative Disorders and XingImaging, LLC · New Haven, CT · Get directions →

    This is a single-center, open-label clinical study designed to evaluate the imaging characteristics and safety of \[¹⁸F\]MODAG-009 in participants with Parkinson's disease (PD), Multiple system atrophy (MSA), and Healthy controls (HC). Approximately 13 participants will be enrolled in this study.

    ✓ Study care freeEarly Phase 1Ages 50–80Learn more →
  • Parkinson's disease

    A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

    Testing a carbidopa and levodopa extended-release capsule in people with Parkinson’s

    📍 Barrow Neurological Institute · Phoenix, AZ · +26 more US sites · Get directions →

    The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Type 2 diabetesHeart / cardiovascular disease

    Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes

    Testing how drinking ketone drinks affects heart function in people with type 2 diabetes and heart

    📍 University of Texas Health Science Center at San Antonio · San Antonio, TX · Get directions →

    This study will provide insight into whether cardiac function changes with oral Ketone Esters (KE) administered to patients with Type 2 Diabetes Mellitus (T2DM) and Heart failure with reduced ejection fraction (HFrEF). Plasma ketones are avidly extracted by cardiac muscle and their uptake is not dependent upon insulin or influenced by insulin resistance.

    ✓ Study care freeEarly Phase 1Ages 18–80Learn more →
  • Parkinson's disease

    Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease

    Testing a new PET brain scan to measure nerve protein buildup in Parkinson’s

    📍 Invicro (dba Perceptive) · New Haven, CT · +1 more US site · Get directions →

    This clinical study is being conducted to learn more about a new imaging drug called \[18F\]MK-0947, which is designed to help doctors see changes in the brain related to Parkinson's disease (PD). PD is a condition that affects movement, balance, and thinking.

    ✓ Study care freeEarly Phase 1Ages 18–80Learn more →
  • Heart / cardiovascular disease

    Improving Coronary Vascular Health in Women

    Testing whether blood flow in heart arteries can be improved in women with HIV

    📍 Massachusetts General Hospital · Boston, MA · Get directions →

    Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may involve reduced ability to increase blood flow through large and small coronary arteries at times when increased flow of oxygen-carrying blood is needed.

    ✓ Study care freePhase 2Ages 45–75WomenLearn more →
  • DepressionParkinson's disease

    Imaging Depression in Parkinson's Disease

    Studying brain changes linked to depression in people with Parkinson’s

    📍 Yale University · New Haven, CT · Get directions →

    The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Parkinson's disease

    Ketamine for Veterans With Parkinson's Disease

    Testing ketamine for depression in veterans with Parkinson’s disease

    📍 San Francisco VA Medical Center, San Francisco, CA · San Francisco, CA · Get directions →

    Parkinson's disease (PD) is a devastating illness that has a growing impact on Veterans. One of the most disabling symptoms is depression, which is common in PD and linked to poor quality of life and higher risk of suicide.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Parkinson's disease

    Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)

    Tracking how brain scans change over time in people with early Parkinson’s

    📍 Institute for Neurodegenerative Disorders · New Haven, CT · +1 more US site · Get directions →

    The study is a longitudinal, multi-center study to assess progression of \[18F\] AV-133 imaging in Prodromal PD participants. Participants will be followed for up to 24 months.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • DepressionParkinson's disease

    Psilocybin Therapy for Depression in Parkinson's Disease

    Testing whether psilocybin therapy improves depression symptoms in people with Parkinson’s disease

    📍 University of California, San Francisco · San Francisco, CA · Get directions →

    The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Parkinson's disease

    Cortical Electrophysiology of Response Inhibition in Parkinson's Disease

    Studying how deep brain stimulation in Parkinson’s affects brain control of stopping actions

    📍 Emory University Hospital · Atlanta, GA · +1 more US site · Get directions →

    Patients with Parkinson's Disease will be studied before, during, and after a deep brain stimulation implantation procedure to see if the stimulation location and the size of the electrical field produced by subthalamic nucleus (STN) DBS determine the degree to which DBS engages circuits that involve prefrontal cortex executive functions, and therefore have a direct impact on the patient's ability to inhibit actions.

    ✓ Study care freePhase 4Ages 45–75Learn more →
  • Parkinson's disease

    A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

    Testing the safety and effect of a gene therapy put into the brain for moderate Parkinson’s disease

    📍 Mayo Clinic · Phoenix, AZ · +33 more US sites · Get directions →

    The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.

    ✓ Study care freePhase 2Ages 45–75Learn more →
  • Heart / cardiovascular diseaseLupus (SLE)

    The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

    Testing whether anifrolumab improves blood vessel risk markers in lupus

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. This can increase the risk of heart attacks or stroke.

    ✓ Study care freePhase 2Ages 18–80Learn more →
  • Parkinson's disease

    Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

    Testing an oral low-dose carbon monoxide liquid in people with Parkinson’s

    📍 Quest Research Institute · Farmington Hills, MI · Get directions →

    A phase 2a multicenter, randomized, double-blind, placebo-controlled multiple dose study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered daily over 14 days in subjects with Parkinson's disease (PD).

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Parkinson's disease

    Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)

    Studying how a brain imaging tracer binds in early Parkinson’s over 24 months

    📍 UAB · Birmingham, AL · Get directions →

    The overall goal of this protocol is to investigate \[18F\]DPA-714 binding in prodromal and early manifest Parkinson's Disease (PD) and to determine the baseline and change from baseline in \[18F\]DPA-714 binding in PD participants during a 24-month interval. Primary Objectives * To compare \[18F\]DPA-714 binding in prodromal and manifest PD and healthy volunteers.

    ✓ Study care freeEarly Phase 1Ages 18–99Learn more →
  • Parkinson's disease

    Pyridostigmine for the Treatment of Constipation in Parkinson Disease

    Testing pyridostigmine as a treatment for constipation in Parkinson disease

    📍 University of Vermont Medical Center · Burlington, VT · Get directions →

    Constipation is a common and debilitating non-motor symptom of Parkinson disease (PD) that often precedes the onset of classic motor symptoms by decades. There is no standardized algorithm for managing constipation in this patient population, nor are there dedicated treatments.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Parkinson's disease

    Rehabilitation of Airway Protection in Parkinson's Disease

    Testing therapy to improve airway protection problems in Parkinson’s

    📍 Purdue University · West Lafayette, IN · +1 more US site · Get directions →

    Airway protective disorders are a prevalent and progressive consequence of Parkinson's Disease (PD), and often result in aspiration pneumonia which is the leading cause of death in PD. Despite this, a large number of patients with PD do not access specialized services to address these critical deficits.

    ✓ Study care freePhase 2Ages 50–90Learn more →
  • Parkinson's disease

    📍 Cornell University Weill Medical College · New York, NY · Get directions →

    This is a phase 1/2 clinical study to evaluate the safety, tolerability, feasibility, and preliminary efficacy of NouvNeu001 in patients with advanced Parkinson's Disease.

    ✓ Study care freePhase 1Ages 30–75Learn more →
  • Dementia / Alzheimer'sParkinson's disease

    18F-mFBG Cardiac Uptake With Lewy Body Dementia

    Testing a heart imaging tracer to see how Lewy body dementia affects nerve signals

    📍 Houston Methodist Neurological Institute · Houston, TX · Get directions →

    This is a Phase 2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of the effect of neurodegenerative diseases on myocardial sympathetic innervation. Effectiveness of 18F-mFBG imaging of the heart will be judged in terms of the quantitative difference between results for subjects with Lewy body and non-Lewy body neurologic disease as compared to historical data for healthy control subjects.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Parkinson's disease

    Tenapanor in Synucleinopathy-Related Constipation

    Testing tenapanor for constipation related to Parkinson’s disease

    📍 Cedar Valley Digestive Health Center · Waterloo, IA · Get directions →

    Investigation of tenapanor as a potential treatment for synucleinopathy-associated constipation

    ✓ Study care freePhase 2Ages 50–89Learn more →
  • Parkinson's disease

    Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease

    Testing how much brain tau buildup is in people with Parkinson’s using PET scans

    📍 Institute for Neurodegenerative Disorders / XingImaging, LLC · New Haven, CT · Get directions →

    The study aims to evaluate the burden of tau pathology in people with Sporadic and LRRK2 PD via in vivo imaging using the tau tracer, \[18F\]PI-2620, and a high resolution PET camera, NeuroEXPLORER.

    ✓ Study care freePhase 2Ages 45–85Learn more →
  • Parkinson's disease

    A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

    Testing two doses of an add-on medicine to levodopa for Parkinson’s with motor fluctuations

    📍 University of Arkansas for Medical Sciences · Little Rock, AR · +24 more US sites · Get directions →

    This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo.

    ✓ Study care freePhase 2Ages 30–80Learn more →
  • Parkinson's disease

    BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease

    Testing a new long-acting levodopa dose to improve “on” time in Parkinson’s

    📍 Cleveland Clinic · Cleveland, OH · Get directions →

    The purpose of this study is to evaluate the effect of IPX203 (Crexont®) - the newest extended-release levodopa formulation - on the duration and quality of good on time, using a wearable device to monitor symptoms. 'Good on time' refers to a period (minutes to hours) when a patient experiences optimal symptom control due to effective medication and has better overall functioning without troublesome dyskinesias.

    ✓ Study care freePhase 4Ages 40+Learn more →
  • High cholesterol

    A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

    Testing how safe and well weekly injections of alirocumab work for high cholesterol in adults

    📍 Anaheim Clinical Trials · Anaheim, CA · +29 more US sites · Get directions →

    This study is researching an experimental drug called alirocumab, referred to as "study drug". In the United States, alirocumab is approved for the treatment of hypercholesterolemia (high blood cholesterol levels).

    ✓ Study care freePhase 2Ages 18–80Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

    Testing how BGE-102 affects inflammation blood tests and safety in people with obesity and heart

    📍 Site 108 · Chandler, AZ · +11 more US sites · Get directions →

    The purpose of this study is to learn about the effects of BGE-102 on blood biomarkers including hsCRP, which is a lab value used to measure inflammation. BGE-102 decreases inflammation which may improve obesity and cardiovascular health.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Parkinson's disease

    Title: A Multimodal Exercise Program With Gamification for Parkinson Disease (MEP+G)

    Testing an 8-week exercise program with boxing and computer games for people with Parkinson disease

    📍 Equilibrium Physical Therapy · Ventura, CA · Get directions →

    In this pilot study the research will explore whether exercises and the outcome measures would be acceptable to conduct a more detailed research study. This 8 week pilot study will utilize a comprehensive exercise program that includes non-contact boxing along with computerized games for individuals with Parkinson Disease.

    ✓ Study care freeEarly Phase 1Ages 40–80Learn more →
  • Parkinson's disease

    Noise-augmented Automatic Speech Recognition for Speech Treatment in Parkinson's Disease

    Testing whether automatic speech recognition feedback improves speech clarity and social

    📍 Teachers College, Columbia University · New York, NY · Get directions →

    The goal of this clinical trial is to learn whether noise-augmented feedback using automatic speech recognition improves intelligibility and social participation in individuals with Parkinson's disease. The main questions the investigators will address are: Does noise-augmented feedback lead to increased intelligibility, as measured by transcription accuracy scores?

    ✓ Study care freeEarly Phase 1Ages 50–80Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Mechanisms of Semaglutide Therapy in Heart Failure Patients

    Testing how semaglutide works in people with heart failure and obesity

    📍 Greenstone Biosciences · Palo Alto, CA · +1 more US site · Get directions →

    Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used for treatment of type-2 diabetes mellitus. GLP-1 receptors are present on pancreatic islet β-cells, δ-cells and α-cells.

    ✓ Study care freePhase 1Ages 20–80Learn more →
  • Parkinson's disease

    rTMS to Improve Cognition in Parkinson's

    Testing whether noninvasive brain stimulation can improve thinking in people with Parkinson’s

    📍 Jesse Brown VA Medical Center, Chicago, IL · Chicago, IL · +1 more US site · Get directions →

    The purpose of this study is to examine safety, feasibility, and the behavioral and brain effects of a non-invasive treatment, repetitive transcranial magnetic stimulation (rTMS), for Veterans with Parkinson's disease or atypical parkinsonism and mild impairments in their thinking. The hypothesis is that rTMS can improve thinking for people with Parkinson's disease or atypical parkinsonism who are experiencing mild problems with their thinking ability.

    ✓ Study care freePhase 1Ages 50+Learn more →
  • Parkinson's disease

    Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

    Comparing treatments to see which works better for hallucinations in Parkinson’s disease

    📍 Southern Arizona VA Health Care System, Tucson, AZ · Tucson, AZ · +23 more US sites · Get directions →

    Patients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking problems. Many patients also have other symptoms not related to movement, called non-motor symptoms, which may affect one's mood or emotions, memory or thinking, or cause one to see or hear things that aren't real (hallucinations) or believe things that aren't true (delusions).

    ✓ Study care freePhase 4Ages 40+Learn more →
  • Parkinson's disease

    Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease

    Testing a wearable sensor that gives feedback for swallowing therapy in Parkinson’s

    📍 Purdue University · West Lafayette, IN · Get directions →

    Dysphagia, or difficulty swallowing, is a common symptom of many neurological diseases but its treatment is not well established or easily accessible. To start addressing this gap, the researchers developed and validated a cost-effective wearable surface electromyography (sEMG) biofeedback sensor technology (i-Phagia), optimized to record muscle activity from the head/neck and provide biofeedback to patients and adherence data to clinicians during swallow therapy.

    ✓ Study care freePhase 2Ages 50–90Learn more →
  • Parkinson's disease

    Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease

    Testing varenicline to reduce falls and improve walking multitasking in Parkinson’s

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    This trial aims to test whether one year of Varenicline, when compared to placebo, can reduce fall risk and show improvement in the ability to multitask while walking. Participants that are eligible after screening for the study will be randomized to receive Varenicline or placebo.

    ✓ Study care freePhase 2Ages 45+Learn more →
  • Dementia / Alzheimer'sParkinson's diseaseMultiple sclerosis (MS)

    Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

    Testing safety of a PET imaging tracer in people with ALS, AD, MS, PD

    📍 UCSF · San Francisco, CA · +2 more US sites · Get directions →

    This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation.

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • Heart / cardiovascular disease

    Canagliflozin Targeting Vascular Inflammation

    Testing canagliflozin to reduce blood vessel inflammation in cardiovascular disease

    💵 May compensate

    📍 University of Ottawa Heart Institute · Ottawa, Ontario · Get directions →

    CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Heart / cardiovascular disease

    Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

    Testing a medicine to see its cardiovascular effects in adults on dialysis

    📍 Nephrology of North Alabama · Decatur, AL · +39 more US sites · Get directions →

    This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Dementia / Alzheimer'sParkinson's disease

    Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia

    Studying how nerve cell loss affects thinking ups and downs in Lewy body dementia

    📍 Virginia Commonwealth University · Richmond, VA · Get directions →

    The proposed study aims to address the critical gaps in understanding the mechanisms of CF (Cognitive Fluctuations) by leveraging recently emerged molecular biomarkers, advanced neuroimaging techniques to assess measures of cholinergic degeneration, and synchronous EEG and assessments of attention. One of the overarching innovations of study is combining all of these assessments into one integrated research plan

    ✓ Study care freePhase 4Ages 50–89Learn more →
  • Parkinson's disease

    A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease

    Testing the safety and side effects of DSP-1083 implanted in people with Parkinson’s disease

    📍 University of Kentucky Medical Center · Lexington, KY · +1 more US site · Get directions →

    The Goal of this study is to evaluate the safety, tolerability, and clinical responses following implantation of DSP-1083. Study enrolls both male and female patients in 2 cohorts.

    ✓ Study care freePhase 1Ages 40–72Learn more →
  • Obesity / overweightHeart / cardiovascular diseaseHigh cholesterol

    Akkermansia Muciniphilia and Metabolic Side Effects of ADT

    Testing how Akkermansia gut bacteria relate to body and blood lipid changes in people with obesity

    📍 London Health Sciences Centre - Victoria Hospital · London, Ontario · Get directions →

    The overriding objectives of this study are: 1. Primary outcomes: 1.

    ✓ Study care freeEarly Phase 1Ages 18+MenLearn more →
  • Obesity / overweightType 2 diabetesHeart / cardiovascular disease

    Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants

    Testing the diabetes medicine pioglitazone in people with type 2 diabetes, obesity, and heart

    📍 Texas Diabetes Institute/UH · San Antonio, TX · Get directions →

    Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main question it aims to answer are: 1.

    ✓ Study care freePhase 4Ages 30–70Learn more →
  • Parkinson's disease

    Multiple Objective Particle Swarm Optimization Postural Instability Gait Disorder

    Testing how scans after deep brain stimulation help assess Parkinson’s gait

    📍 University of Minnesota · Minneapolis, MN · Get directions →

    Sixty patients will be enrolled in this study who are treated for Parkinson's disease (PD) with bilateral deep brain stimulation of subthalamic nucleus (STN) or globus pallidus (GP), who have a pre- operative 7 Tesla MRI including diffusion tensor imaging for tractography and a postoperative head CT for electrode localization, and in whom at least 3 months have passed since activation of their neurostimulators, for stabilization of clinical stimulator settings. Using their MRI and CT, the investigators will construct patient-specific models of electrical current spread to neuroanatomical tar- gets surrounding the electrode.

    ✓ Study care freeEarly Phase 1Ages 18–89Learn more →
  • Parkinson's disease

    Personalized Real-Time DBS and PD Mechanisms

    Studying how closed-loop deep brain stimulation and levodopa affect Parkinson’s motor symptoms

    📍 Cleveland Clinic · Cleveland, OH · Get directions →

    A prospective cohort of patients scheduled to undergo deep brain stimulation (DBS) implantation surgery for the treatment of Parkinson's disease as per standard of care will be invited to participate in this study. This mechanistic study is aimed at better understanding the role of basal ganglia beta band (11-35 Hz) oscillations and resonance in the manifestation of Parkinson's disease (PD) motor signs using closed-loop electrical neurostimulation, levodopa medication, and computational modeling.

    ✓ Study care freePhase 4Ages 18–80Learn more →
  • High cholesterolLupus (SLE)

    IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

    Testing certolizumab added to usual treatment to improve pregnancy in lupus and antiphospholipid

    📍 Hospital for Special Surgery · New York, NY · +1 more US site · Get directions →

    This treatment trial evaluates the addition of an anti-tumor necrosis factor-alpha drug, certolizumab, to usual treatment (a heparin agent and low-dose aspirin) in pregnant women with antiphospholipid syndrome (APS) and repeatedly positive tests for lupus anticoagulant (LAC) to determine if this regimen will improve pregnancy outcomes. All enrolled patients will receive certolizumab, and pregnancy outcomes will be compared to those of women with APS and repeatedly positive tests for LAC enrolled in a previous study by the investigators.

    ✓ Study care freePhase 2Ages 18–40WomenLearn more →
  • Parkinson's disease

    The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy

    Testing brain inflammation in people with Parkinson’s using PET scans

    📍 UAB Advanced Imaging Facility · Birmingham, AL · Get directions →

    The primary objective of this substudy is to measure the concentration and the regional brain distribution of activated brain microglia/macrophages using the PET ligand \[18F\]DPA-714 in participants enrolled in the UAB Innate and Adaptive Immunity in Parkinson's Disease (Clinical Research Core) and Longitudinal \[18F\]DPA-714 Imaging in a Parkinson Disease Cohort studies. The PET tracer \[18F\]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia/macrophages and provides a non-invasive measure of neuroinflammation.

    ✓ Study care freePhase 1Ages 30+Learn more →
  • Heart / cardiovascular diseaseDementia / Alzheimer's

    Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults

    Testing whether lowering cholesterol in older adults affects heart and memory outcomes

    📍 University of Alabama at Birmingham · Birmingham, AL · +37 more US sites · Get directions →

    PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo.

    ✓ Study care freePhase 4Ages 75+Learn more →
  • Heart / cardiovascular disease

    Ertugliflozin in Chronic Heart Failure

    Testing ertugliflozin and other medicines for heart failure symptoms

    📍 Yale School of Medicine · New Haven, CT · Get directions →

    The purpose of this study is to determine the effects on heart failure signs and symptoms of the use of either ertugliflozin, metolazone or placebo, in conjunction with intravenous loop diuretic use in acute settings and chronic oral loop diuretic therapy. There are two general purposes for this study.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Heart / cardiovascular disease

    Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions

    Testing stem cell treatment for safety and effects on heart disease

    📍 Southern California Hospital at Culver City / Southern California Hospital at Hollywood / Multiple US-based Sub-Investigator Sites · Culver City, CA · Get directions →

    This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of stem cell therapy for the treatment of various acute and chronic conditions. Clinically observed initial findings and an extensive body of research indicate regenerative treatments are both safe and effective for the treatment of multiple conditions.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Heart / cardiovascular diseaseHigh blood pressure

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

    Studying how vitamin C affects blood vessel function in obese adults with insulin resistance and

    📍 University of Kansas Medical Center · Kansas City, KS · Get directions →

    The main purpose of research is to examine and understanding the development of hypertension in obese adults with insulin resistance. Findings from our studies will identify unique mechanisms that can be targeted to limit increases in vascular dysfunction and reduce the excessively high prevalence of hypertension and risk for cardiovascular disease (CVD).

    ✓ Study care freePhase 1Ages 35–65Learn more →
  • Obesity / overweightHeart / cardiovascular diseaseHigh blood pressure

    PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis

    Testing timing of blood pressure medicines in people with obesity and high blood pressure

    📍 University of Alabama at Birmingham · Birmingham, AL · Get directions →

    Obese individuals have a higher prevalence of nocturnal hypertension and non-dipping blood pressure (BP). These conditions are associated with an increased risk of cardiovascular (CV) events and death.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Parkinson's disease

    Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease

    Testing nasal insulin and glutathione added to usual care in people with Parkinson’s

    📍 Institute for Neuroimmune Medicine · Davie, FL · +2 more US sites · Get directions →

    This study will be evaluating the safety and efficacy of insulin and glutathione in subjects with Parkinson's Disease compared to placebo.

    ✓ Study care freePhase 2Ages 30+Learn more →
  • Parkinson's disease

    Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

    Measuring serotonin 2A brain receptor activity in people with Parkinson’s

    📍 Vanderbilt University Medical Center · Nashville, TN · Get directions →

    It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\[18F\]MH.MZ in both populations.

    ✓ Study care freePhase 4Ages 50–85Learn more →
  • DepressionParkinson's disease

    Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's Disease

    Testing whether a 12-week multi-strain probiotic can treat depression in people with Parkinson’s

    📍 Pacific Parkinson's Research Centre · Vancouver, British Columbia · Get directions →

    This study evaluates the use of an oral multi-strain probiotic in the treatment of depression in individuals with Parkinson's Disease. Participants will be randomized to either a 12-week multi-strain probiotic treatment or placebo intervention.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Dementia / Alzheimer'sParkinson's disease

    Comparing Antipsychotic Medications in LBD Over Time

    Comparing medicines to see which works better for hallucinations or delusions in Lewy body disease

    📍 University Health System · San Antonio, TX · +1 more US site · Get directions →

    The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).

    ✓ Study care freePhase 4Learn more →
  • Type 2 diabetesHeart / cardiovascular disease

    Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

    Testing tirzepatide to see if it slows plaque buildup in heart arteries in people with type 2

    📍 Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute) · Torrance, CA · Get directions →

    A multi-center, randomized, double-blind, placebo-controlled, parallel-group phase IV Study evaluating the effects of tirzepatide on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of type II Diabetes (T2DM) and atherosclerosis.

    ✓ Study care freePhase 4Ages 40–80Learn more →
  • Heart / cardiovascular diseaseKidney disease

    Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

    Testing dapagliflozin with standard care on heart and lung function and blood metabolites in chronic

    📍 Northwestern University · Chicago, IL · Get directions →

    The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created when our bodies break down food, drugs, or its own tissues) in patients with chronic kidney disease.

    ✓ Study care freePhase 1Ages 18–85Learn more →
  • Showing the first 60 of 62. Add filters or a location to narrow down.